OncoSynergy
Stamford, US · Delaware corporation · 1 known investors
OncoSynergy develops monoclonal antibodies for immuno-oncology, including first-in-class pan-CD29 and best-in-class PD1-targeting candidates. The company is focused on cancer immunotherapy.
Founders & leadership
AS
Allen SalmasiDirector
AC
Anne-Marie CarbonellExecutive Officer, Director
HS
Hen Suh ParkDirector
RD
Robert DunkleDirector
WS
W. Shawn CarbonellExecutive Officer, Director
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$6.6MraisedMay 2026 · 5 investors · BiotechnologyRule 506(b)
▶$6.6MraisedMay 2026 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Allen SalmasiDirector
- Anne-Marie CarbonellExecutive Officer, Director
- Hen Suh ParkDirector
- Offering amount
- $8.2M
- Amount sold
- $6.6M
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedMay 2022 · 4 investors · BiotechnologyRule 506(b)
▶$3.5MraisedMay 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Colin FosterDirector
- Allen SalmasiDirector
- Anne-Marie CarbonellExecutive Officer, Director
- Hen Suh ParkDirector
- Offering amount
- $7.3M
- Amount sold
- $3.5M
- Sales commissions
- $46.6K
- Placement agents
- Kelson Capital
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedSep 2020 · 6 investors · BiotechnologyRule 506(b)
▶$3.3MraisedSep 2020 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anne-Marie CarbonellExecutive Officer, Director
- Colin FosterDirector
- Robert DunkleDirector
- Allen SalmasiDirector
- Hen Suh ParkDirector
- Offering amount
- $5M
- Amount sold
- $3.3M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedMay 2018 · 23 investors · BiotechnologyRule 506(b)
▶$20MraisedMay 2018 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert DunkleDirector
- W. Shawn CarbonellExecutive Officer, Director
- Allen SalmasiDirector
- Hen Suh ParkDirector
- Anne-Marie CarbonellExecutive Officer
- Offering amount
- $21M
- Amount sold
- $20M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- The Innovators: OncoSynergy - CANCER FUNDcancerfund.com · 2021
- OncoSynergy makes series A headway -globalventuring.com · 2018
- OncoSynergy Raises Series A Funding Round - FinSMEsfinsmes.com · 2018
- DanDrit Biotech USA Inc. Announces The Purchase Of OncoSynergy, Inc.prnewswire.com · 2016
- OncoSynergy raises Series A Round to Accelerate Clinical Development of its Glioblastoma Program | UCSF Helen Diller Family Comprehensive Cancer Centercancer.ucsf.edu